BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31247148)

  • 1. Identification of a New Inhibitor That Stabilizes Interleukin-2-Inducible T-Cell Kinase in Its Inactive Conformation.
    Hantani R; Hanawa S; Oie S; Umetani K; Sato T; Hantani Y
    SLAS Discov; 2019 Sep; 24(8):854-862. PubMed ID: 31247148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of inactive conformation-selective interleukin-2-inducible T-cell kinase (ITK) inhibitors based on second-harmonic generation.
    Hantani Y; Iio K; Hantani R; Umetani K; Sato T; Young T; Connell K; Kintz S; Salafsky J
    FEBS Open Bio; 2018 Sep; 8(9):1412-1423. PubMed ID: 30186743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosensor-based approach to the identification of protein kinase ligands with dual-site modes of action.
    Navratilova I; Macdonald G; Robinson C; Hughes S; Mathias J; Phillips C; Cook A
    J Biomol Screen; 2012 Feb; 17(2):183-93. PubMed ID: 22068706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FLiK: a direct-binding assay for the identification and kinetic characterization of stabilizers of inactive kinase conformations.
    Simard JR; Rauh D
    Methods Enzymol; 2014; 548():147-71. PubMed ID: 25399645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors.
    Han S; Czerwinski RM; Caspers NL; Limburg DC; Ding W; Wang H; Ohren JF; Rajamohan F; McLellan TJ; Unwalla R; Choi C; Parikh MD; Seth N; Edmonds J; Phillips C; Shakya S; Li X; Spaulding V; Hughes S; Cook A; Robinson C; Mathias JP; Navratilova I; Medley QG; Anderson DR; Kurumbail RG; Aulabaugh A
    Biochem J; 2014 Jun; 460(2):211-22. PubMed ID: 24593284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potent inhibitors for interleukin-2-inducible T-cell kinase: structure-based virtual screening and molecular dynamics simulation approaches.
    Meganathan C; Sakkiah S; Lee Y; Narayanan JV; Lee KW
    J Mol Model; 2013 Feb; 19(2):715-26. PubMed ID: 23015102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three mechanistically distinct kinase assays compared: Measurement of intrinsic ATPase activity identified the most comprehensive set of ITK inhibitors.
    Kashem MA; Nelson RM; Yingling JD; Pullen SS; Prokopowicz AS; Jones JW; Wolak JP; Rogers GR; Morelock MM; Snow RJ; Homon CA; Jakes S
    J Biomol Screen; 2007 Feb; 12(1):70-83. PubMed ID: 17166826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk).
    Tang G; Liu L; Wang X; Pan Z
    Eur J Med Chem; 2019 Jul; 173():167-183. PubMed ID: 30999237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
    Zhao H; Huang D; Caflisch A
    ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of type-II inhibitors using kinase structures.
    Lovering F; McDonald J; Whitlock GA; Glossop PA; Phillips C; Bent A; Sabnis Y; Ryan M; Fitz L; Lee J; Chang JS; Han S; Kurumbail R; Thorarensen A
    Chem Biol Drug Des; 2012 Nov; 80(5):657-64. PubMed ID: 22759374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescence labels in kinases: a high-throughput kinase binding assay for the identification of DFG-out binding ligands.
    Simard JR; Rauh D
    Methods Mol Biol; 2012; 800():95-117. PubMed ID: 21964785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of an Allosteric, Inactive Conformation-Selective Inhibitor of Full-Length HPK1 Utilizing a Kinase Cascade Assay.
    Wang W; Mevellec L; Liu A; Struble G; Miller R; Allen SJ; Federowicz K; Wroblowski B; Vialard J; Ahn K; Krosky D
    Biochemistry; 2021 Oct; 60(41):3114-3124. PubMed ID: 34608799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.
    Charrier JD; Miller A; Kay DP; Brenchley G; Twin HC; Collier PN; Ramaya S; Keily SB; Durrant SJ; Knegtel RM; Tanner AJ; Brown K; Curnock AP; Jimenez JM
    J Med Chem; 2011 Apr; 54(7):2341-50. PubMed ID: 21391610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformational Selectivity of ITK Inhibitors: Insights from Molecular Dynamics Simulations.
    Ogawa N; Ohta M; Ikeguchi M
    J Chem Inf Model; 2023 Dec; 63(24):7860-7872. PubMed ID: 38069816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and structure-activity relationship of indolylindazoles as potent and selective covalent inhibitors of interleukin-2 inducible T-cell kinase (ITK).
    Wang X; Xue G; Pan Z
    Eur J Med Chem; 2020 Feb; 187():111918. PubMed ID: 31830635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of fragment screening methods on the p38α kinase: new methods, new insights.
    Pollack SJ; Beyer KS; Lock C; Müller I; Sheppard D; Lipkin M; Hardick D; Blurton P; Leonard PM; Hubbard PA; Todd D; Richardson CM; Ahrens T; Baader M; Hafenbradl DO; Hilyard K; Bürli RW
    J Comput Aided Mol Des; 2011 Jul; 25(7):677-87. PubMed ID: 21732248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
    Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.
    Smith CR; Dougan DR; Komandla M; Kanouni T; Knight B; Lawson JD; Sabat M; Taylor ER; Vu P; Wyrick C
    J Med Chem; 2015 Jul; 58(14):5437-44. PubMed ID: 26087137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of inter-domain stabilizers-a novel assay system for allosteric akt inhibitors.
    Fang Z; Simard JR; Plenker D; Nguyen HD; Phan T; Wolle P; Baumeister S; Rauh D
    ACS Chem Biol; 2015 Jan; 10(1):279-88. PubMed ID: 24959717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Flavonoids as Putative ROS-1 Kinase Inhibitors Using Pharmacophore Modeling for NSCLC Therapeutics.
    Parate S; Kumar V; Hong JC; Lee KW
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33917039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.